These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines. Bodle J; Vandenberg K; Laurie K; Barr IG; Zhang Y; Rockman S Front Immunol; 2023; 14():1147028. PubMed ID: 37033922 [TBL] [Abstract][Full Text] [Related]
4. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025 [TBL] [Abstract][Full Text] [Related]
5. Potency determination of inactivated H7 influenza vaccines using monoclonal antibody-based ELISA and biolayer interferometry assays. Vasudevan A; Woerner A; Schmeisser F; Verma S; Williams O; Weir JP Influenza Other Respir Viruses; 2018 Mar; 12(2):250-258. PubMed ID: 29152878 [TBL] [Abstract][Full Text] [Related]
6. A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines. Schmeisser F; Vasudevan A; Soto J; Kumar A; Williams O; Weir JP Influenza Other Respir Viruses; 2014 Sep; 8(5):587-95. PubMed ID: 25087462 [TBL] [Abstract][Full Text] [Related]
7. Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines. Legastelois I; Chevalier M; Bernard MC; de Montfort A; Fouque M; Pilloud A; Serraille C; Devard N; Engel O; Sodoyer R; Moste C J Virol Methods; 2011 Dec; 178(1-2):129-36. PubMed ID: 21907241 [TBL] [Abstract][Full Text] [Related]
8. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines. Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response. de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382 [TBL] [Abstract][Full Text] [Related]
10. Conformationally selective biophysical assay for influenza vaccine potency determination. Wen Y; Han L; Palladino G; Ferrari A; Xie Y; Carfi A; Dormitzer PR; Settembre EC Vaccine; 2015 Oct; 33(41):5342-5349. PubMed ID: 26348403 [TBL] [Abstract][Full Text] [Related]
11. Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies. Ferrara F; Del Rosario JMM; da Costa KAS; Kinsley R; Scott S; Fereidouni S; Thompson C; Kellam P; Gilbert S; Carnell G; Temperton N Front Immunol; 2021; 12():661379. PubMed ID: 34108964 [TBL] [Abstract][Full Text] [Related]
12. Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings. Wen Y; Palladino G; Xie Y; Ferrari A; Ma X; Han L; Dormitzer PR; Settembre EC Vaccine; 2016 Jun; 34(29):3388-95. PubMed ID: 27154389 [TBL] [Abstract][Full Text] [Related]
13. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses. Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P J Virol; 2017 May; 91(9):. PubMed ID: 28179535 [TBL] [Abstract][Full Text] [Related]
14. An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. Rajendran M; Sun W; Comella P; Nachbagauer R; Wohlbold TJ; Amanat F; Kirkpatrick E; Palese P; Krammer F PLoS One; 2018; 13(4):e0194830. PubMed ID: 29617394 [TBL] [Abstract][Full Text] [Related]
15. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity. Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201 [TBL] [Abstract][Full Text] [Related]
17. Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion. Bodle J; Verity EE; Ong C; Vandenberg K; Shaw R; Barr IG; Rockman S Influenza Other Respir Viruses; 2013 Mar; 7(2):191-200. PubMed ID: 22583601 [TBL] [Abstract][Full Text] [Related]
18. Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies. Nakajima R; Supnet M; Jasinskas A; Jain A; Taghavian O; Obiero J; Milton DK; Chen WH; Grantham M; Webby R; Krammer F; Carter D; Felgner PL; Davies DH mSphere; 2018 Dec; 3(6):. PubMed ID: 30541779 [TBL] [Abstract][Full Text] [Related]
19. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency. Khurana S; King LR; Manischewitz J; Coyle EM; Golding H Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520 [TBL] [Abstract][Full Text] [Related]